Neuregen opens Phase 1 gene therapy trial for recurrent high-grade glioma
NRG-103 enters dose-finding testing in glioma patients who have exhausted chemoradiotherapy, targeted therapy, or immunotherapy, in a field with no validated disease-modifying mechanism.
Executive Summary
- Neuregen Therapeutics has opened its first registered clinical trial, a Phase 1 dose-finding study of the gene therapy NRG-103 in patients with high-grade glioma that has come back or kept growing despite treatment.
- The study enrolls only patients who have run out of standard options, tying the trial's relevance directly to how poorly the current late-line treatment landscape serves this group.
- Gene therapy remains a thinly used approach in this disease compared with the small molecules, devices, and radiopharmaceuticals that dominate the active trial landscape, so this entry tests a mechanism with little same-modality precedent to draw on.
- Because the design centers on safety and tolerability rather than a controlled efficacy comparison, the trial's near-term value is establishing whether the approach can be dosed safely, not whether it works.
The trial
Neuregen Therapeutics Co., Ltd. is recruiting patients for a Phase 1 study of NRG-103 injection, its first clinical trial on record, across three sites in China. The trial targets 24 patients and carries a primary completion date of April 30, 2030, more than three years out from its July 9, 2026 start. The primary endpoints are adverse events, serious adverse events, and adverse events of special interest measured over two years, alongside dose-limiting toxicity assessed at eight weeks; six-month progression-free survival is tracked as a secondary measure. That structure marks this as a safety and dose-finding study designed to establish a tolerable dose range and a recommended dose for later testing, not a controlled efficacy trial. NCT07710690A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade GliomaNCT07710690
Who qualifies
Enrollment is restricted to adults with a WHO Grade 3 or 4 glioma diagnosis, confirmed by pathology report, who have already failed or proven intolerant to chemoradiotherapy, targeted therapy, or immunotherapy, evidenced by grade 3 or higher non-hematologic toxicity or grade 4 hematologic toxicity. Recurrence or progression must be confirmed on MRI under RANO 2.0 criteria. Patients with prior gene therapy or oncolytic virus treatment are excluded. That eligibility bar defines a population with no recognized effective treatment remaining, the setting in which any tolerability or early efficacy signal from NRG-103 would be read. NCT07710690A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade GliomaNCT07710690
The competitive landscape
Gene therapy has been used in only 4 of the trials active in high-grade glioma, a landscape otherwise built around small molecules such as Nuvation Bio's safusidenib and Day One Biopharmaceuticals' tovorafenib, devices such as NovoCure's Optune, and radiopharmaceuticals such as Telix Pharmaceuticals' TLX101-Tx, none of which share NRG-103's modality or a resolved target. The nearest modality precedent is Trogenix's TGX-007, an AAV-mediated dual-payload gene therapy also in Phase 1/2 testing for high-grade glioma. The only agent with an approval specific to high-grade glioma in the roster is carmustine's Gliadel Wafer, an alkylating implant, indicated as an adjunct to surgery and radiation in newly diagnosed disease and as an adjunct to surgery in recurrent glioblastoma. With no validated disease-modifying systemic mechanism established for this late-line population, a result that shows manageable toxicity across escalating doses, together with any six-month progression-free survival signal that holds up as enrollment matures, would be the finding that gives this entrant standing beyond a safety readout. NCT07710690A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade GliomaNCT07710690
The sponsor
This is Neuregen Therapeutics' only trial on record, giving it no prior track record in this or any other indication to draw on. The trial has logged no protocol amendments since its registration and carries a stable designation on that basis. Its risk profile is otherwise unremarkable for a trial at this stage: it just opened, it is actively recruiting, and its enrollment target matches its anticipated count with no shortfall to assess yet. NCT07710690A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade GliomaNCT07710690
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.